Uniqure B.V. Stock
€13.93
Your prediction
Uniqure B.V. Stock
Pros and Cons of Uniqure B.V. in the next few years
Pros
Cons
Performance of Uniqure B.V. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Uniqure B.V. | 3.500% | 2.962% | 5.404% | 149.540% | -17.373% | -35.144% | -57.878% |
| Ironwood Pharmaceuticals | 0.000% | 18.033% | 55.396% | -75.229% | -74.286% | -90.314% | -87.368% |
| Novocure Ltd | -0.590% | 1.186% | -0.146% | -36.429% | -64.852% | -87.684% | -84.868% |
| Iovance Biotherapeutics Inc. | -7.600% | -4.199% | -21.984% | -79.627% | -69.939% | -82.290% | -91.605% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financials of Uniqure, a player in the Biotechnology & Medical Research industry, depict a company grappling with significant challenges but also hints of potential growth. The data shows a precarious situation marked by escalating liabilities and negative earnings, but there are underlying indicators that may point to future improvements. This analysis dives deeper into the positives and negatives found within the financial statements, cash flows, income statements, and ratios.
Starting with an overview, Uniqure’s balance sheet presents a troubling picture. Total assets for 2023 amount to approximately $831.7 million, but the total liabilities stand at $624 million, resulting in a stockholder equity of just $207.7 million. Also alarming is the retained earnings, which sits at a staggering -$890.4 million, reflecting long-term operational losses. However, despite these troubling figures, the liquidity appears relatively healthy, with a net working capital of approximately $578 million, suggesting that Uniqure can meet its short-term obligations.
*Pros: *